• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.

    5/15/26 11:33:37 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COLL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)


    COLLEGIUM PHARMACEUTICAL, INC

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)




    19459J104

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    19459J104


    1Names of Reporting Persons

    Eventide Asset Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,424,282.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,424,282.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,424,282.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP Number(s):
    19459J104


    1Names of Reporting Persons

    Finny Kuruvilla, M.D. Ph. D.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,424,282.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,424,282.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,424,282.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP Number(s):
    19459J104


    1Names of Reporting Persons

    Robin C. John
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,424,282.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,424,282.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,424,282.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    COLLEGIUM PHARMACEUTICAL, INC
    (b)Address of issuer's principal executive offices:

    100 Technology Center Drive, Stoughton, MA 02072
    Item 2. 
    (a)Name of person filing:

    (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John")
    (b)Address or principal business office or, if none, residence:

    Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110
    (c)Citizenship:

    Eventide: Delaware Kuruvilla: United States John: United States
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    19459J104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (i) Eventide: 1,424,282 (ii) Kuruvilla: 1,424,282 (iii) John: 1,424,282
    (b)Percent of class:

    (i) Eventide: 4.5% (ii) Kuruvilla: 4.5% (iii) John: 4.5%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (1) Eventide: 1,424,282 (2) Kuruvilla: 0 (3) John: 0

     (ii) Shared power to vote or to direct the vote:

    (1) Eventide: 0 (2) Kuruvilla: 1,424,282 (3) John: 1,424,282

     (iii) Sole power to dispose or to direct the disposition of:

    (1) Eventide: 1,424,282 (2) Kuruvilla: 0 (3) John: 0

     (iv) Shared power to dispose or to direct the disposition of:

    (1) Eventide: 0 (2) Kuruvilla: 1,424,282 (3) John: 1,424,282

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Eventide Asset Management, LLC
     
    Signature:/s/ Peter J. Luiso
    Name/Title:Peter J. Luiso, General Counsel
    Date:05/15/2026
     
    Finny Kuruvilla, M.D. Ph. D.
     
    Signature:/s/ Finny Kuruvilla, M.D., Ph. D.
    Name/Title:Finny Kuruvilla, M.D., Ph. D.
    Date:05/15/2026
     
    Robin C. John
     
    Signature:/s/ Robin C. John
    Name/Title:Robin C. John
    Date:05/15/2026
    Exhibit Information

    EXHIBIT 1 - Filed Herewith

    Get the next $COLL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COLL

    DatePrice TargetRatingAnalyst
    12/9/2025$58.00Overweight
    Barclays
    1/10/2025$46.00Hold → Buy
    Needham
    7/30/2024$47.00Neutral → Buy
    H.C. Wainwright
    6/7/2024$41.00 → $44.00Hold → Buy
    Jefferies
    5/10/2024Buy → Hold
    Needham
    5/10/2024$39.00Overweight → Neutral
    Piper Sandler
    1/4/2024$30.00 → $37.00Buy → Hold
    Jefferies
    8/25/2023$35.00 → $36.00Buy
    Needham
    More analyst ratings

    $COLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Collegium Pharmaceutical with a new price target

    Barclays initiated coverage of Collegium Pharmaceutical with a rating of Overweight and set a new price target of $58.00

    12/9/25 8:43:40 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Pharmaceutical upgraded by Needham with a new price target

    Needham upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $46.00

    1/10/25 8:00:15 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Pharmaceutical upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Collegium Pharmaceutical from Neutral to Buy and set a new price target of $47.00

    7/30/24 6:32:12 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Collegium to Participate in 2026 Jefferies Global Healthcare Conference

    STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. Details of the event are as follows: Fireside Chat Date and Time: Wednesday, June 3, 2026, at 1:20 p.m. ETNew York, NY A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Collegium Pharmaceutical, Inc.Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering

    5/27/26 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

    – Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 – – Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition – – 2026 Total Product Revenues, Net Expected in the Range of $865 to $895 Million and Adjusted EBITDA in the Range of $475 to $500 Million – STOUGHTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), today announced that it has completed the acquisition of AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a cent

    5/12/26 7:31:46 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress

    – Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year –  – Generated JORNAY PM® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS® in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Generated Quarterly Pain Portfolio Net Revenues of $154.6 Million, Up 4% Year-over-Year – – Ended Q1'26 with Cash, Cash Equivalents and Marketable Securities of $421.8 Million – – Reaffirmed Full-Year 2026 Guidance for the Current Business – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., May 07

    5/7/26 7:30:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    SEC Filings

    View All

    SEC Form S-8 filed by Collegium Pharmaceutical Inc.

    S-8 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

    6/1/26 4:47:36 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Collegium Pharmaceutical Inc.

    S-8 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

    6/1/26 4:46:14 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Pharmaceutical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

    5/15/26 4:10:34 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Freund John Gordon sold $681 worth of shares (20 units at $34.05), decreasing direct ownership by 0.02% to 83,952 units (SEC Form 4)

    4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

    5/20/26 4:05:09 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bohlin Garen G was granted 8,741 shares, increasing direct ownership by 14% to 71,000 units (SEC Form 4)

    4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

    5/18/26 4:15:21 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Freund John Gordon was granted 8,741 shares, exercised 8,700 shares at a strike of $16.49 and sold $142,547 worth of shares (4,127 units at $34.54), increasing direct ownership by 19% to 83,972 units (SEC Form 4)

    4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

    5/18/26 4:15:22 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Financials

    Live finance-specific insights

    View All

    Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

    – Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 – – Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition – – 2026 Total Product Revenues, Net Expected in the Range of $865 to $895 Million and Adjusted EBITDA in the Range of $475 to $500 Million – STOUGHTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), today announced that it has completed the acquisition of AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a cent

    5/12/26 7:31:46 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress

    – Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year –  – Generated JORNAY PM® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS® in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Generated Quarterly Pain Portfolio Net Revenues of $154.6 Million, Up 4% Year-over-Year – – Ended Q1'26 with Cash, Cash Equivalents and Marketable Securities of $421.8 Million – – Reaffirmed Full-Year 2026 Guidance for the Current Business – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., May 07

    5/7/26 7:30:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium to Report First Quarter 2026 Financial Results on May 7, 2026

    STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2026 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Comp

    4/23/26 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Announces Updates to its Board of Directors and Executive Leadership Team

           – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, today announced updates to its Board of Directors and appointments of three new executive leaders as the C

    3/17/25 7:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Appoints Nancy S. Lurker to its Board of Directors

    STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. "Collegium is pleased to welcome Nancy to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Nancy's expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions." "This is a pivotal and exciting time for Collegium as it embarks on a new stage of growth

    2/5/25 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Collegium Pharmaceutical Inc.

    SC 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    11/13/24 5:13:28 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc.

    SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    11/13/24 4:30:24 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

    SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    2/14/24 12:04:28 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care